Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS

被引:23
作者
Buskin, SE
Newcomer, LM
Koutsky, LA
Hooton, TM
Spach, DH
Hopkins, SG
机构
[1] Seattle King Cty Dept Publ Hlth, Seattle, WA USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Seattle, WA USA
[4] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1999年 / 20卷 / 02期
关键词
HIV infection; bacterial infections; trimethoprim-sulfamethoxazole; Pneumocystis carinii pneumonia; AIDS mortality;
D O I
10.1097/00042560-199902010-00014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To measure the effect of trimethoprim-sulfamethoxazole (TMP-SMX) in preventing bacterial illness, Pneumocystis carinii pneumonia (PCP), and death in people with AIDS, we conducted a retrospective medical record review of 1078 persons who were observed for 3 years on average who attended nine outpatient facilities in Seattle, Washington between January 1990 and April 1996. We calculated relative risk estimates to measure the protective effect of TMP-SMX on the development of major bacterial illnesses, PCP, and death. Use of TMP-SMX decreased the risk of PCP (relative risk [RR] = 0.23; 95% confidence interval [CI], 0.14-0.36) and deaths not attributable to PCP (RR = 0.59; 95% CI, 0.47-0.73). Prevention of major bacterial illnesses of known etiology was of borderline significance (RR = 0.77; 95% CI, 0.57-1.05) and became statistically significant with the addition of patients with infections of unknown etiology (RR = 0.77; 95% CI 0.61-0.97). Use of TMP-SMX PCP prophylaxis significantly reduced the risks of death and of PCP and was associated with a trend toward reduced risk of major bacterial infections.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 21 条
[1]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[2]   MICROBIOLOGY OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA IN PERSONS WITH AND AT RISK FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION - IMPLICATIONS FOR RATIONAL EMPIRIC ANTIBIOTIC-THERAPY [J].
BURACK, JH ;
HAHN, JA ;
SAINTMAURICE, D ;
JACOBSON, MA .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (22) :2589-2596
[3]  
Caumes E, 1997, ANN MED INTERNE, V148, P172
[4]   PNEUMOCYSTIS PROPHYLAXIS AND SURVIVAL IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION TREATED WITH ZIDOVUDINE [J].
CHAISSON, RE ;
KERULY, J ;
RICHMAN, DD ;
MOORE, RD .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (10) :2009-2013
[5]  
Cohn D L, 1991, Infect Dis Clin North Am, V5, P485
[6]   Community-acquired bacteremia in HIV-positive patients: Protective benefit of co-trimoxazole [J].
Edge, MD ;
Rimland, D .
AIDS, 1996, 10 (14) :1635-1639
[7]   SPECTRUM OF DISEASE IN PERSONS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN THE UNITED-STATES [J].
FARIZO, KM ;
BUEHLER, JW ;
CHAMBERLAND, ME ;
WHYTE, BM ;
FROELICHER, ES ;
HOPKINS, SG ;
REED, CM ;
MOKOTOFF, ED ;
COHN, DL ;
TROXLER, S ;
PHELPS, AF ;
BERKELMAN, RL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (13) :1798-1805
[8]   ACCESS TO THERAPY IN THE MULTICENTER AIDS COHORT STUDY, 1989-1992 [J].
GRAHAM, NMH ;
JACOBSON, LP ;
KUO, V ;
CHMIEL, JS ;
MORGENSTERN, H ;
ZUCCONI, SL .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (09) :1003-1012
[9]   A CONTROLLED TRIAL OF TRIMETHOPRIM SULFAMETHOXAZOLE OR AEROSOLIZED PENTAMIDINE FOR SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - AIDS CLINICAL-TRIALS GROUP PROTOCOL-021 [J].
HARDY, WD ;
FEINBERG, J ;
FINKELSTEIN, DM ;
POWER, ME ;
HE, W ;
KACZKA, C ;
FRAME, PT ;
HOLMES, M ;
WASKIN, H ;
FASS, RJ ;
POWDERLY, WG ;
STEIGBIGEL, RT ;
ZUGER, A ;
HOLZMAN, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (26) :1842-1848
[10]   BACTERIAL PNEUMONIA IN PERSONS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS [J].
HIRSCHTICK, RE ;
GLASSROTH, J ;
JORDAN, MC ;
WILCOSKY, TC ;
WALLACE, JM ;
KVALE, PA ;
MARKOWITZ, N ;
ROSEN, MJ ;
MANGURA, BT ;
HOPEWELL, PC ;
STANSELL, J ;
TURNER, J ;
OSMOND, D ;
MERRIFIELD, C ;
MOSSAR, M ;
HIRSCHTICK, R ;
MEISELMAN, L ;
MANGHISI, KJ ;
SCHNEIDER, RF ;
REICHMAN, LB ;
MANGURA, B ;
BARNES, S ;
RICHER, B ;
AU, J ;
COULSON, A ;
CLEMENTE, V ;
SARAVOLATZ, LD ;
JOHNSON, C ;
HUITSING, J ;
KRYSTOFORSKI, A ;
POOLE, WK ;
RAO, AV ;
CLAYTON, K ;
HANSON, N ;
JORDAN, M ;
THOMPSON, J ;
MYERS, D ;
LAVANGE, L ;
KATZIN, J ;
FULKERSON, W ;
WILCOSKY, T ;
LOU, Y ;
KALICA, AR ;
WITTES, J ;
FOLLMANN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (13) :845-851